Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for perioperative myocardial injury prevention in CCS with type 2 diabetes undergoing elective PCI
ChiCTR2300075232Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin in Chronic Coronary Syndrome (CCS), type 2 diabetes mellitus (T2DM), Myocardial injury and 1 more (2 arms), sponsored by Beijing Hospital. Primary endpoints: Periprocedural myocardial injury and Type 4a myocardial infarction. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
Chronic Coronary Syndrome (CCS)type 2 diabetes mellitus (T2DM)Myocardial injurymyocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2300075232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075232.